Viyash Scientific
Q2 revenue ₹988 Cr (+16.2%) and PAT ₹85 Cr (+16.1%) are real but base-aided. Q2 EBITDA margin fell to 21.1% from 22.1%, and management leans on 2028-30 launches.
ALFA Concalls
Every earnings call, live and summarised
Earnings calls
Every Viyash Scientific earnings call we streamed: the live audio and our summary of what management said.
Q2 revenue ₹988 Cr (+16.2%) and PAT ₹85 Cr (+16.1%) are real but base-aided. Q2 EBITDA margin fell to 21.1% from 22.1%, and management leans on 2028-30 launches.
Q2 revenue ₹988 Cr (+16.2%) and PAT ₹85 Cr (+16.1%) are real but base-aided. Q2 EBITDA margin fell to 21.1% from 22.1%, and management leans on 2028-30 launches.
Guides PAT growth above 50% in FY27 (H1 +49%). Capex ~₹150 Cr over two years. ₹20 Cr loan prepayment considered; Europe launch next year.
Viyash reports a robust Q1FY27 with 20% revenue growth and significantly expanded EBITDA margins at 21.6%. The company is essentially net-debt free following successful integration and is pivoting toward high-potent oncology products.
Viyash Scientific targets a $1Bn revenue platform by 2032 through the merger of Sequent and Viyash Life Sciences, focusing on animal and human health.
Viyash reports a transformative Q4 FY26 with EBITDA surpassing ₹200cr. Revenue rose 19.1% YoY to ₹920cr, driven by integration synergies and a shift toward high-potent human and animal health products.
Viyash delivered a breakout FY26 with Q4 EBITDA crossing 200cr, marking a successful business integration.
Viyash Q4 FY26 revenue reached ₹9,200 Mn with 21.7% EBITDA margins. Management highlights successful integration and a deleveraged balance sheet.
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.